Drug Trial Radar · NCT02499328
Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
340
Actual
Start
Aug 6, 2015
Primary completion
Feb 28, 2020
Study completion Oct 8, 2025
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- MedImmune LLC
- First posted
- Jul 16, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicentre, open-label, Phase 1b/2 study is designed as a 2 part study consisting of a dose-escalation, safety run-in Part A and a dose-expansion Part B
Conditions
- Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck
Interventions
AZD9150Drug
AZD9150
MEDI4736Drug
MEDI4736
AZD5069Drug
AZD5069
tremelimumab (treme)Drug
tremelimumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Danvatirsen With Durvalumab MTDs (Maximum Tolerated Dose) or Recommended Doses for Dose-expansionTime frame: 35 days
- Part A: AZD5069 With Durvalumab MTDs (Maximum Tolerated Dose) or Recommended Doses for Dose-expansionTime frame: 35 days
- Part A: Safety and Tolerability in Terms of Adverse EventsTime frame: At every treatment and follow up visit until disease progression, an average of 1 year.
- Part B: ORR (Objective Response Rate) in Patients With IL/2L RM-SCCHN.Time frame: Assessed at every even-numbered cycles with RECIST until disease progression, up to 12 months.
Locations
44 sites in 6 countries. Site status is shown where the registry gives one.
Research Site
Birmingham, Alabama
Research Site
Duarte, California
Research Site
La Jolla, California
Research Site
Los Angeles, California
Research Site
Los Angeles, California
Research Site
Orange, California
Research Site
San Francisco, California
Research Site
Denver, Colorado
Research Site
Plantation, Florida
Research Site
Sarasota, Florida
Research Site
Lafayette, Indiana
Research Site
Boston, Massachusetts
Research Site
Detroit, Michigan
Research Site
Billings, Montana
Research Site
Morristown, New Jersey
Research Site
Cincinnati, Ohio
Research Site
Houston, Texas
Research Site
Fairfax, Virginia
Research Site
Seattle, Washington
Research Site
Antwerp, Belgium
Research Site
Brussels, Belgium
Research Site
Brussels, Belgium
Research Site
Edegem, Belgium
Research Site
Namur, Belgium
Research Site
Berlin, Germany
Research Site
Cologne, Germany
Research Site
Dresden, Germany
Research Site
Frankfurt, Germany
Research Site
Hamburg, Germany
Research Site
Hanover, Germany
Research Site
Jena, Germany
Research Site
München, Germany
Research Site
Milan, Italy
Research Site
Barcelona, Spain
Research Site
Hospitalet deLlobregat, Spain
Research Site
Madrid, Spain
Research Site
Madrid, Spain
Research Site
Toledo, Spain
Research Site
Birmingham, United Kingdom
Research Site
London, United Kingdom
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.